<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E504E398-B748-4347-8610-49A4168A3384"><gtr:id>E504E398-B748-4347-8610-49A4168A3384</gtr:id><gtr:firstName>Gillian</gtr:firstName><gtr:surname>Murphy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400637"><gtr:id>74367C82-0D13-4626-8F1E-0281707F342E</gtr:id><gtr:title>Novel approaches for the control of metalloproteinases in the modulation of pericellular events</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400637</gtr:grantReference><gtr:abstractText>We are studying the enzymes that regulate the environmental cues that cells receive from their neighbouring cells and the tissue matrix and that can act as determinants of disease progression. These protein degrading enzymes, proteinases are numerous and have over lapping structures and properties, We plan to make novel inhibitory molecules that prevent the action of individual proteinases by binding to them in a very specific way. We contend that such inhibitors will teach us more about the way that proteinases function and will give guidelines for the design of new inhibitors with therapeutic potential against diseases such as cancer.
Communication of our results is largely achieved through scientific means (publications, poster presentations, web sites) and departmental Open days. GM has also been involved in telephone interviews with the media and has spoken on local radio.</gtr:abstractText><gtr:technicalSummary>The members of the matrix metalloproteinase (MMP) and disintegrin metalloproteinase (ADAM) families are vital players in proteolytic mechanisms for the regulation of cell function by the modulation of their microenvironment. Due to the subtle structural and substrate specificity differences in these proteinases, the development of specific inhibitors represents an enormous challenge. We propose that the use of generic approaches to develop antibody fragments as inhibitors of individual proteinases, binding either the catalytic domain, or key features of their ecto domains presents a promising novel approach to this problem. Such reagents will also throw light on the molecular mechanisms of action of the target enzymes. We will also further evaluate the natural inhibitors, TIMPs, and their specific interactions with individual metalloproteinases, using both random and systematic mutagenesis techniques to define new generations of TIMP inhibitors as potential therapeutics.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>462918</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (G0802007: Identification of membrane-type 1 matrix metalloproteinase as a novel therapeutic target of Rheumatoid Arthritis)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5D168F53-4360-4C5A-9302-A26C3F06EC44</gtr:id><gtr:outcomeId>63412C505280</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Antibodies specific for metalloproteases have been developed</gtr:description><gtr:id>F1FEE3ED-C966-4C5A-BE05-AF787826EC8D</gtr:id><gtr:impact>None yet as work not completed</gtr:impact><gtr:outcomeId>ED49004B839</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>scFv antibodies</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D6694B6F-2552-49D9-893B-939AB20DF782</gtr:id><gtr:title>Assessment of gelatinase expression and activity in articular cartilage.</gtr:title><gtr:parentPublicationTitle>Methods in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bd3f029d5b92dec7e924c1568575452"><gtr:id>1bd3f029d5b92dec7e924c1568575452</gtr:id><gtr:otherNames>Hembry RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1543-1894</gtr:issn><gtr:outcomeId>05409147BFA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCC06346-4127-461C-8787-519085AEF9C2</gtr:id><gtr:title>Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5d63d550e53a446aada819f6953bd2d"><gtr:id>d5d63d550e53a446aada819f6953bd2d</gtr:id><gtr:otherNames>Boutet P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>585d4e1219b4b7.56266420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBA1BFB0-3B95-4485-8C73-1228D81F1577</gtr:id><gtr:title>The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1509ec5091436632e2d5a9338cd2cdf8"><gtr:id>1509ec5091436632e2d5a9338cd2cdf8</gtr:id><gtr:otherNames>Lee MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn><gtr:outcomeId>2EC2ECF2B00</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDFDCD95-1DF4-4211-ACE2-91284C8C1009</gtr:id><gtr:title>Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1509ec5091436632e2d5a9338cd2cdf8"><gtr:id>1509ec5091436632e2d5a9338cd2cdf8</gtr:id><gtr:otherNames>Lee MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>2A9EBE56F34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B35A76DE-20E4-4411-9C09-65E336D274FA</gtr:id><gtr:title>MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5843fdcb016f0ca4067a5cca30fbb587"><gtr:id>5843fdcb016f0ca4067a5cca30fbb587</gtr:id><gtr:otherNames>Atkinson SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>ED4B13B0DD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>839DD22E-1B86-4BD4-8C73-CFF81B59925A</gtr:id><gtr:title>Individual Timp deficiencies differentially impact pro-MMP-2 activation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be8c5550421fa09ac979fdf852cadab"><gtr:id>3be8c5550421fa09ac979fdf852cadab</gtr:id><gtr:otherNames>English JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>9A5A103C502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63E237B6-61F2-4A36-BCB3-68B77A4CBE8C</gtr:id><gtr:title>Characterization of the AB loop region of TIMP-2. Involvement in pro-MMP-2 activation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e250a6317bb69b2ce351d7e324a249e6"><gtr:id>e250a6317bb69b2ce351d7e324a249e6</gtr:id><gtr:otherNames>Rapti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>46415EEEC84</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400637</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>